RxDoctor Payments Data

Garrick Simmons, MD

Urology · Missoula, MTNPI 1912940693

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,975 of the $16,345 with a category attached, or 91.6%. AbbVie accounts for 92.9% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $15,208 and has fallen 99.6% since, to $56 in 2025. Among urology clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,345in general payments, 2019–2025

Across 66 payments — averaging $247.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$15K
  • Astellas Pharma US Inc$241
  • Pfizer$168
  • Rochester Medical Corporation$134
  • Dendreon Pharmaceuticals LLC$131
  • Boston Scientific$84
  • plus $410 from 12 others

What the payments were for

  • Consulting fees$14,97592%
  • Food & beverage$1,3708%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)14$15,177
Astellas Pharma US Inc7$241
Pfizer10$168
Rochester Medical Corporation7$134
Dendreon Pharmaceuticals LLC6$131
Boston Scientific3$84
Bayer1$75
Amgen4$71
Johnson & Johnson3$54
Laborie Medical Technologies Corp.2$37
Teleflex LLC2$34
180 Medical, Inc.1$31
Merck1$31
Endo Pharmaceuticals Inc.1$18
Dornier Medtech America, Inc1$18
Profound Medical Corp.1$14
C. R. Bard, Inc. & Subsidiaries1$14
Coloplast1$13

How this compares

$16,345 in reported general payments places this provider in the 95th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$268,778
Medicare patients
504
Services billed
3,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$291,253
OrgovyxRelugolix42$110,757
Abiraterone Acetate73$79,919
MyrbetriqMirabegron27$27,918
Tamsulosin Hcl132$2,067
Potassium Citrate ErPotassium Citrate13$1,206
Prednisone49$278
Finasteride22$254
CefuroximeCefuroxime Axetil12$230
Oxybutynin Chloride ErOxybutynin Chloride14$205
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$82
Tramadol Hcl36$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$241$319,17147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 urology providers in Montana.

Other urology in Missoula

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →